Release Summary

Biothera Pharmaceuticals will present data tomorrow demonstrating the unique immune response profile of its Phase 2 cancer immunotherapy drug at the EORTC-NCI-AACR symposium in Munich, Germany.

Biothera Pharmaceuticals, Inc.